Browse News
Filter News
Found 808,507 articles
-
The first Bioversity cohort includes several graduates placed at Massachusetts life sciences companies.
-
How to Deal With Layoff-Related Stress
4/18/2024
Employees worried about layoffs can practice self-care, use employer resources and contact a mental health professional, if needed. -
Plus, what to expect in a phone screen and how to handle an impending layoff.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
TaiGen Successfully Completes TG-1000 Phase III Study
4/18/2024
TaiGen Biotechnology Company, Limited announces that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study.
-
Morphoceuticals Names Jim Jenson, PhD as CEO to Advance AI-Guided Regenerative Medicine Technology
4/18/2024
Morphoceuticals Inc. announced the appointment of veteran biotech executive Jim Jenson, PhD, as CEO. Jenson joins a growing team and will lead the company as it advances its novel regenerative medicine technology platform.
-
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
4/18/2024
Cerevel Therapeutics announced positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon, the first and only D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease.
-
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and...
4/18/2024
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, recently completed two Phase 3 trials, OA-07 long-term structure, pain and function study, and OA-21 short-term pain study.
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
4/18/2024
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.
-
Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
4/18/2024
BEYFORTUS ® (nirsevimab) is the first long-acting antibody approved in Canada for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants through their first RSV season.
-
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
4/18/2024
Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has raised $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as well as support from existing investors including Canaan and Brandon Capital.
-
Notice of Annual General Meeting in Cantargia AB (publ) - April 18, 2024
4/18/2024
Cantargia The shareholders of Cantargia AB are invited to the annual general meeting on Thursday, 23 May 2024, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden.
-
Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases
4/18/2024
Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
-
Interim report Q1, 2024: Strong growth in APAC and solid margins
4/18/2024
Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.
-
Cellares Launches Cell Q, the World’s First Automated cGMP QC Workcell for Cell Therapies, to Resolve Manual QC Processing Bottleneck and Extend IDMO Capabilities from Manufacturing Through Quality Control
4/18/2024
Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today unveiled Cell Q™, the first automated quality control (QC) workcell for cell therapy manufacturing.
-
Hansa Biopharma interim report January-March 2024
4/18/2024
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and year-end report for January to March 2024.
-
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
4/18/2024
Biotricity Inc. announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics.
-
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
4/18/2024
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.
-
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
4/18/2024
Biophytis SA announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity.